13 Sep 2017

(2428 votes)

Virotherapy In Germany: Mode of Action, Clinical Use, And Rigvir® Cost

Chances are you've been looking into Rigvir® for a while. And whether it is the Rigvir® price or clinical use that you would like to learn more about, you are on the right page. Before we dive into the practical side of the question, let’s take a brief look at the Rigvir® timeline.

Rigvir® Was Discovered In the 1950s And Since Then Has Proved Its Treating Power For Melanoma Patients, Followed By Entering The Market In 2005

The unique feature of virotherapy is Rigvir®, a virus for cancer treatment. It traces its roots back to the 1950’s when a Latvian microbiologist, professor Aina Muceniece discovered that a particular virus living in the digestive system of babies possessed a powerful cancer cell killing capacity.

In 1968, 415 melanoma patients whose cells remained unresponsive to chemo and radio participated in the clinical trial of Rigvir®. The research has proven that Rigvir® is epidemiologically safe (combats and prevents infectious diseases) and has a healing effect in melanoma treatment.

In the following decades, patients diagnosed with skin melanoma and other types of cancer were successfully treated with Rigvir®. The virus entered the market in 2005 and has spread throughout 20 countries around the world, including Germany and Mexico.

In 2005, the drug was registered in Latvia. In 2015 and 2016 Rigvir® was approved by the national registration authorities in Georgia and Armenia accordingly. In 2016, Rigvir® producing company received funding from the European Commission program “Horizon 2020” taking one more step forward to be registered in Europe.

How Rigvir® Works: Stored In Cooled Vials For Injections Into Muscles

Being a powerful anti-cancer virus, Rigvir® seeks and infects malignant cells inside your body. It then quickly replicates inside the cells and stays laser-focused on their destruction. Because cancer cells usually camouflage themselves as healthy ones, Rigvir® unveils their mask and mobilizes your entire immune system to fight the disease.

Rigvir in Germany

The Clinical Use Of Rigvir® Confirms That The Virus Can Treat Skin and Eye Melanoma, Stomach and Rectal Cancer

Between 1968 and 2004 over 700 patients suffering from late-stage melanoma, gastric and gastrointestinal cancer were involved in clinical studies with the medicine [1]. The results obtained have shown the following:

  • The 3-year survival rate for melanoma patients treated with surgery only was 46-58%, while patients that were also treated with Rigvir® had a 3-year survival rate of 57–84% and a 5-year survival rate of 44–66%
  • The 3- and 5-year survival rate for ocular melanoma patients made 90% and 70%, respectively
  • The 5-year survival rate for stage III stomach cancer patients after surgery was 24–33%, compared to 47–60% for those who received treatment with Rigvir®
  • The 5-year survival rate for stage II-IV rectal cancer patients after surgery was 41–68%, compared with 71–78% for those who received treatment with Rigvir®[1]

What Types Of Cancer Rigvir® Can Also Treat — Solid Tumours Only

  • sarcomas: lymphosarcoma, angiosarcoma, leiomyosarcoma, reticulosarcoma, and rhabdomyosarcoma
  • colorectal cancer
  • pancreatic cancer
  • bladder cancer
  • prostate cancer
  • kidney cancer
  • uterine cancer
  • breast cancer
  • ovarian cancer
  • neuroendocrine tumors
  • glioblastoma

How Safe Is Rigvir®? Affects Only Malignancies While Healthy Tissues Are Untouched And Causes Little Side Effects

  1. Because Rigvir® leaves healthy cells untouched, it has shown little or no side effects. Specifically, the body temperature may rise up to 99.5 °F/37.5 °C and stay such for up to three days.

  2. Additionally, Rigvir® cannot reproduce itself in a human body outside the cancer cell.

  3. Rigvir® can be combined with other standard cancer treatments including surgery, chemotherapy, and radiotherapy.

How Much Does Rigvir® Treatment Cost? 6,000 EUR (6,670 USD) Per 1-Week Therapy in Germany

Virotherapy package in Germany is two times less expensive than that in Mexico or Australia. But because you’ll get the instructions first hand from the clinic with no hidden extra costs or pitfalls having plenty of time for flight booking and other pre-travel arrangements.

Rigvir in Germany Rigvir in Germany Rigvir in GermanyRigvir in GermanyRigvir in GermanyRigvir in Germany

You have access to Rigvir® treatment along with other anti-cancer therapies in Germany. Other than meals, accommodation, and transfers the treatment package normally includes:

  • Rigvir® therapy
  • Hyperthermia
  • Detox
  • Acupuncture
  • Buserelin Therapy
  • Targeted Radionuclide Therapy

On average such treatment package costs 6,000  EUR (6,670 USD) per week.

To Get The Treatment In Germany, Collect Digital Versions Of Medical Records And Send Them To Us For Case Evaluation

We understand that you would like to know if you or the one you love can be qualified for the Rigvir® virotherapy as soon as possible. To do that, the medical team first needs to perform case evaluation based on the following recent medical records of yours:

  • blood count including white blood cells
  • radiological findings (CT or MRI)
  • histopathological findings
  • cytological findings
  • medical report

The oncologist will assess your case free of charge and forward you the reply within 48–72 hours from the moment you provide all necessary files.

To submit the medical documentation, please, click the button below. In case you have some questions, we can also answer them within 24 hours.

“I’m Eligible For Rigvir® Treatment and Packing My Things To Visit Germany. What Is Included Into My Treatment Package, Except For Rigvir®?”

  1. Transfer from and to Munich International Airport.
  2. Daily medical and administrative support provided by caring English-speaking personnel.
  3. Final check-ups whether you’re not allergic to Rigvir®.
  4. Consultations with an oncologist, immunologist, nutritiologist and other specialists.
  5. Tailor-made healthy diet for you.
  6. Nice accommodation at the clinic that looks like a countryside house rather than a sterile clinic.
  7. Possibility to enhance your virotherapy with additional medical activities. All of them can be combined with Rigvir® and can be conducted only under the doctors’ control.

Additional Therapies Include Buserelin, Detox, Hyperthermia, Targeted Radionuclide Therapy, Minimally-Invasive Surgery Etc.

These terms may confuse you, so let’s explain what all of these therapies imply.

Buserelin therapy suits well to treat prostate and breast cancer. Its chemical formula reminds reproductive hormones allowing it to regulate them in a patient’s body and fight cancer.

Detox is recommended as a lifestyle: it implies taking care of your body and mind by eating healthy organic food with vitamins and minerals, having enough physical activity to feel well.

Hyperthermia (local) is aimed at fighting prostate cancer cells via the use of high temperatures.

Targeted Radionuclide Therapy also works well for combating prostate cancer: it uses small particles with radioactive elements to eliminate malignant cells from your body. It doesn’t affect the whole body and doesn’t cause severe side effects as radiotherapy does.

Minimally-invasive (or gentle) surgery was designed to help your body to recover more rapidly than after a conventional operation. It’s done via small cuts.

Of course, you won’t be prescribed all of them, but depending on your health conditions doctors can suggest you having more than 1 therapy.

In this article we’ve tried to answer all the possible questions. If we’ve missed any, contact us via the red button. We’ll be happy to give you detailed answers.

List of References

  1. Brūvere, R., O., Heisele A. Ferdats, A. Rupais, and A. Muceniece, Echovirus-mediated biotherapy for malignant tumours: 40 years of investigation. Acta medica Lituanica, 2002. Suppl. 9: p. 97-100.
  2. “Adapted ECHO-7 Virus RigVir Immunotherapy (oncolytic Virotherapy) Prolongs Survival in Melanoma Patients after Surgical Excision of the Tumour in a Retrospective Study.” Doniņa, Simona; Strēle, Ieva; Proboka, Guna; Auziņš, Jurgis; Alberts, Pēteris; Jonsson, Björn; Venskus, Dite; Muceniece, Aina. Melanoma Research: October 2015 - Volume 25 - Issue 5 - p 421–426.
  3. Alberts, P., E. Olmane, L. Brokāne, Z. Krastiņa, M. Romanovska, K. Kupčs, S. Isajevs, G. Proboka, R. Erdmanis, J. Nazarovs, and D. Venskus, Long-term treatment with the oncolytic ECHO-7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient-three case reports. APMIS, 2016. 124(10): p. 896-904.